Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: FPLA changes; Nutroganics in soy market; spiked product, supplement-beverage warnings; Kamil chairs CRN

This article was originally published in The Tan Sheet

Executive Summary

FPLA changes proposed; Nutroganics invests to reach soy market; Shoreside hits spiked ingredient trifecta; NYSW blurs supplement-beverage line; Kamil elected CRN chair; and more news in brief.

You may also be interested in...



Relaxation Potion Warning: Wake Up Call About FDA Beverage Guidance

FDA warning letter on Dewmar’s Lean Slow Motion…Potion line is the first addressing differences between products marketed as conventional beverages and as liquid supplements since a final guidance in January. Attorney Justin Prochnow says the warning could signal an FDA crackdown on melatonin in conventional beverages.

FDA Sunsets VCRP, Will Launch New Portal For Mandatory Cosmetics Registration Under MoCRA

FDA is closing down its 50-year-old Voluntary Cosmetic Registration Program as it prepares a new portal for facility registration and product/ingredient listing under the Modernization of Cosmetic Regulations Act. The Independent Beauty Association says the news marked an important step, but dismayed many stakeholders who hoped VCRP data would transfer to the new system or otherwise be preserved.

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel